

## Tranexamic Acid

October 19, 2023

---

Permanent rules for direct entry midwifery became effective on May 1, 2023, which included adding the use of Tranexamic Acid (TXA) as an anti-hemorrhagic administered by intravenous infusion, to the list of approved legend drugs a licensed direct entry midwife (LDM) may administer for maternal use.

**QUESTION 1:** Why is the Board adding TXA now?

**ANSWER 1:** The Board determined that using TXA as an anti-hemorrhagic has different benefits than using the synthetic oxytocin (Pitocin, Syntocin); Methylergonovine (Methergine); Ergonovine (Ergotrate), or Misoprostol (Cytotec).

**QUESTION 2:** How may a LDM use TXA?

**ANSWER 2:** A LDM may use TXA as an anti-hemorrhagic administered by intravenous infusion for maternal use.

**QUESTION 3:** If an LDM chooses to purchase or administer TXA are they required to obtain training prior to use?

**ANSWER 3:** Yes, an LDM must obtain education and training related to TXA prior to purchasing or administering TXA in accordance with OAR 331-026-0000(7). There is not a minimum number of hours, or an examination required within the education and training specific to TXA. However, it is the LDM's responsibility to obtain education and training on all direct entry midwifery services they provide including the administration of TXA.

**QUESTION 4:** Is an LDM required to obtain TXA education and training if they do **not** want to purchase or administer TXA?

**ANSWER 4:** No. An LDM is **not** required to obtain TXA education and training.

**QUESTION 5:** Is an LDM required to obtain INITIAL continuing education specific to legend drugs and devices?

## Tranexamic Acid (TXA) FAQ, continued

**ANSWER 5:** Yes. Prior to an LDMs first renewal an LDM must obtain 40 hours of INITIAL continuing education specific to legend drugs and devices pursuant to OAR 332-020-0010(3).

**QUESTION 6:** Is an LDM required to obtain continuing education specific to legend drugs and devices?

**ANSWER 6:** Yes. Pursuant to OAR 332-020-0010(1) an LDM must obtain 35 hours of continuing education every two-years of the 35 hours of continuing education five hours must be related to legend drugs and devices listed under OAR 332-020-0010(2).

**QUESTION 7:** Is there any education and training currently available related to TXA?

**ANSWER 7:** Yes, the Oregon Midwifery Council (OMC) currently offers an online education and training session for TXA. For more information visit the OMC [website](#) or contact continuing education coordinator Emily Born.

HLO has published this information as a courtesy to OMC and licensees. The publishing of this information by HLO should not be interpreted as the HLO or the Board endorsing or approving the TXA education and training session offered by the OMC. It is each individual licensee's responsibility to obtain adequate education and training before administering or purchasing any legend drug or device.

**QUESTION 8.** What additional responsibilities does a LDM have related to accessing and administering legend drugs and devices, such as TXA?

**ANSWER 8:** A LDM that chooses to purchase or administer legend drugs and devices is required to:

- Comply with local, state, and federal laws and regulations regarding administration, distribution, storage, transportation, and disposal.
- Inventory and securely store legend drugs, including samples.
- Record certain information regarding legend drugs and devices and maintain records for five years.

Please see [OAR Chapter 332, Division 26](#) for additional information and full requirements. It is the LDM's responsibility to comply with all rules listed [OAR Chapter 332](#).